News Features When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles Todd Neale September 28, 2021
News Daily News Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label Todd Neale September 20, 2021
News Conference News HFSA 2021 Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF Michael O'Riordan September 14, 2021
News Conference News HFSA 2021 PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF Todd Neale September 13, 2021
News Conference News ESC 2021 In HFrEF, AI Shows Promise For Predicting Beta Blocker Response Yael L. Maxwell September 03, 2021
News Conference News ESC 2021 EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF Todd Neale August 27, 2021
News Daily News Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t Shelley Wood August 04, 2021
News Daily News Retracted Over Fraud Concerns, Surgisphere ACE/ARB Study Still Gets Cited Michael O'Riordan August 03, 2021
News Conference News HRS 2021 Heart Failure Patients With AF Benefit From Early Rhythm Control Shelley Wood July 30, 2021
News Conference News TVT 2021 Optimizing Medical Therapy Before Clip Repair for MR? ‘This Is Hard’ Todd Neale July 27, 2021
News Daily News Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists Todd Neale July 09, 2021
News Conference News ESC Heart Failure 2021 Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR Shelley Wood July 06, 2021
News Daily News Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results Todd Neale July 06, 2021
News Daily News Less Cancer Among HF Patients Taking Statins, Registry Shows Michael O'Riordan June 23, 2021
News Daily News Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors Michael O'Riordan June 16, 2021
News Daily News Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds L.A. McKeown June 03, 2021
News Daily News Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care Shelley Wood May 27, 2021
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News ACC 2021 Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs Todd Neale May 18, 2021
News Conference News ACC 2021 PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI L.A. McKeown May 15, 2021